November 18th 2024
More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.
November 16th 2024
DAPA-HF Reveals Reduced Death, Hospitalizations from HF with Dapagliflozin
September 1st 2019Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.
Trial Shows Metformin with Liraglutide Promising for Children with Type 2 Diabetes
August 21st 2019Metformin as monotherapy is the preferred treatment for children and teens with type 2 diabetes, but a new study published in the Aug. 15 issue of the New England Journal of Medicine suggests that adding liraglutide to the treatment can more effectively control glycemic levels.
FDA Decision on Icosapent sNDA Delayed for Advisory Committee Meeting
August 9th 2019The committee meeting, tentatively scheduled for November 14, will have to precede the sNDA PDUFA action date set to review the drug's potential indication for reducing residual cardiovascular risks in patients with elevated triglycerides.
Definitive Evidence Supports Plant-Based Diet to Control Diabetes
A systematic review and meta-analysis of observational studies assessing the association between plant-based dietary patterns and the risk of type 2 diabetes among adults, provides the strongest evidence to date that eating a plant-based diet does indeed lower the risk of type 2 diabetes.